SGMO News and Press, Sangamo Therapeutics Inc. From 02/25/21

Image source: The Motley Fool. Sangamo Therapeutics Inc (NASDAQ: SGMO) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 p.m. ET Operator Continue reading For further details see: Sangamo Therapeutics Inc (SGMO) Q4 2020 Earnings Call Transcript ...

Sangamo Therapeutics, Inc. (SGMO) Q4 2020 Earnings Conference Call February 24, 2021 5:00 PM ET Company Participants Aron Feingold - Head of Corporate Communications Sandy Macrae - Chief Executive Officer Bettina Cockroft - Senior Vice President and Chief Medical Officer Jason Fontenot - Seni...

Sangamo Therapeutics (SGMO): Q4 GAAP EPS of -$0.29 misses by $0.08.Revenue of $25.8M (-53.0% Y/Y) misses by $5.62M.2021 Guidance: On a GAAP basis, we expect total operating expenses in the range of approximately $285 million to $305 million in 2021, which includes non-cash stock-based compens...

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business highlights. “We are very pleased with our...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The press release will be followed by a c...

BioMarin received a CRL last August which delayed approval by 2 years. Other competitors may be catching up. Yet, BioMarin is still the clear leader in targeting hemophilia A via gene therapy. For further details see: BioMarin's Hemophilia A Treatment: An Assessment

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President and Head of Development. Dr. Schott will lead clinical strategy across all phases of development and regulatory approval and will...

The following slide deck was published by Sangamo Therapeutics, Inc. in conjunction with this event. For further details see: Sangamo Therapeutics (SGMO) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

MorphoSys AG (MOR) names Sung Lee, coming from Sangamo Therapeutics (SGMO) and Gilead Sciences (GILD), as the company's new chief financial officer, effective Feb. 2, 2021.Lee succeeds Jens Holstein, who stepped down in Dec. 2020, and will lead all corporate finance f...

Sangamo Therapeutics (SGMO) announces today that CFO Sung Lee is leaving the company to pursue a new opportunity overseas. Mr. Lee’s last day of employment will be February 1, 2021.“Sung has contributed significantly to Sangamo’s evolution, helping us build...